DE69918283D1 - Stabilisierte herpesvirusformulierung - Google Patents

Stabilisierte herpesvirusformulierung

Info

Publication number
DE69918283D1
DE69918283D1 DE69918283T DE69918283T DE69918283D1 DE 69918283 D1 DE69918283 D1 DE 69918283D1 DE 69918283 T DE69918283 T DE 69918283T DE 69918283 T DE69918283 T DE 69918283T DE 69918283 D1 DE69918283 D1 DE 69918283D1
Authority
DE
Germany
Prior art keywords
herpesvirus
stabilized
virus
formulation
aminoacids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918283T
Other languages
English (en)
Other versions
DE69918283T2 (de
Inventor
Alison Varley
Thomas Loudon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Pharmaceuticals Research Ltd
Original Assignee
Cantab Pharmaceuticals Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Research Ltd filed Critical Cantab Pharmaceuticals Research Ltd
Publication of DE69918283D1 publication Critical patent/DE69918283D1/de
Application granted granted Critical
Publication of DE69918283T2 publication Critical patent/DE69918283T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE1999618283 1998-04-24 1999-04-26 Stabilisierte herpesvirusformulierung Expired - Fee Related DE69918283T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9808922 1998-04-24
GB9808922A GB9808922D0 (en) 1998-04-24 1998-04-24 Virus preparations
PCT/GB1999/001295 WO1999055348A2 (en) 1998-04-24 1999-04-26 Stabilised virus preparation

Publications (2)

Publication Number Publication Date
DE69918283D1 true DE69918283D1 (de) 2004-07-29
DE69918283T2 DE69918283T2 (de) 2005-07-21

Family

ID=10831020

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1999618283 Expired - Fee Related DE69918283T2 (de) 1998-04-24 1999-04-26 Stabilisierte herpesvirusformulierung

Country Status (12)

Country Link
US (1) US6258362B1 (de)
EP (1) EP1071438B1 (de)
JP (1) JP2002512970A (de)
AT (1) ATE269712T1 (de)
AU (1) AU3718299A (de)
CA (1) CA2329000C (de)
DE (1) DE69918283T2 (de)
DK (1) DK1071438T3 (de)
ES (1) ES2224646T3 (de)
GB (1) GB9808922D0 (de)
PT (1) PT1071438E (de)
WO (1) WO1999055348A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AU2001278337A1 (en) * 2000-07-31 2002-02-13 Aventis Pasteur Limited Respiratory syncytial virus vaccine
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
AU2008201215B2 (en) * 2001-12-10 2010-11-18 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
ATE300954T1 (de) * 2001-12-10 2005-08-15 Bavarian Nordic As Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
DK1614426T3 (da) * 2003-02-20 2009-04-06 Cnic Ct Nac Investigaciones Svækkede stammer af Vibrio cholerae og lyofiliserede vacciner, som indeholder disse
CA2552328A1 (en) * 2004-01-15 2005-08-04 Intervet International B.V. Non-animal origin stabilizers and processes for producing the same
US8916175B2 (en) * 2004-06-29 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection
JP5110696B2 (ja) * 2004-11-05 2012-12-26 ウェルスタット バイオロジクス コーポレイション 安定かつ濾過可能なエンベロープで覆われたウイルス処方物
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
KR20080044258A (ko) * 2005-08-04 2008-05-20 와이어쓰 수의용 백신을 위한 안정화제
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
ES2470340T3 (es) 2005-12-28 2014-06-23 Advanced Bionutrition Corporation Vehículo de administración para bacterias probi�ticas que comprende una matriz seca de polisac�ridos, sac�ridos y polioles en forma vítrea
WO2008079539A2 (en) 2006-11-09 2008-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant herpesvirus with diminished latency and methods of using same
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
WO2010044365A1 (ja) * 2008-10-17 2010-04-22 国立大学法人東京海洋大学 鮮度測定用試薬キット
EP3266448B1 (de) 2009-03-27 2022-02-16 Intervet International B.V. Impfstoffe in mikropartikelform zur oralen oder nasalen impfung und stärkung von tieren einschliesslich fischen
AU2010254235B2 (en) * 2009-05-26 2015-04-02 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
BR112012018839B1 (pt) 2010-01-28 2020-04-14 Advanced Bionutrition Corp composição vítrea seca compreendendo um material bioativo
MX350047B (es) 2010-08-13 2017-08-24 Advanced Bionutrition Corp Composicion de estabilizacion de almacenamiento en seco para materiales biologicos.
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
ES2765880T3 (es) 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
EP2852662B1 (de) * 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesviruszusammensetzungen und zugehörige verfahren
FR3024780B1 (fr) * 2014-08-07 2018-11-30 Bertin Pharma Reactif pret a l'emploi
EP3328215B1 (de) 2015-07-29 2021-07-07 Advanced BioNutrition Corp. Stabile trockene probiotische zusammensetzungen für spezielle diätverwendungen
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
US20220193222A1 (en) * 2018-11-30 2022-06-23 Vaccine Stabilization Institute Viral formulations containing amino acids
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
CN116270500B (zh) * 2021-12-30 2025-05-06 安徽贝金基因科技有限公司 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209738C (de)
GB960850A (en) * 1961-09-08 1964-06-17 Wellcome Found Measles virus vaccine
JPS4848621A (de) * 1971-10-20 1973-07-10
JPS4868730A (de) * 1971-12-21 1973-09-19
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5648488B2 (de) * 1973-06-06 1981-11-16
JPS5341202B2 (de) * 1974-03-12 1978-11-01
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
AU532186B2 (en) * 1978-07-21 1983-09-22 Merck & Co., Inc. Herpes virus vaccine
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0048194A3 (de) * 1980-08-28 1982-09-01 Merck & Co. Inc. Verfahren zur Lyophilisierung
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
HU183765B (en) * 1981-12-23 1984-05-28 Phylaxia Oltoanyagtermeloe Process for producing lyophilized vaccine against duck hepatitis
ZA874625B (en) 1986-06-30 1988-10-26 Smith Kline Rit Stabilizers for live vaccines,process for their preparation and vaccines containing them
JPS63230851A (ja) * 1987-03-20 1988-09-27 Sumitomo Metal Ind Ltd 耐食性に優れた油井管用低合金鋼
IE61575B1 (en) 1987-05-04 1994-11-16 Merck & Co Inc A stable lyophilized live herpes virus vaccine
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
JPS63307827A (ja) 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
FR2633518B1 (fr) 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
KR100372934B1 (ko) 1990-09-25 2003-12-24 캔탑 파마슈티칼스 리서취 리미티드 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
DK0713397T3 (da) 1992-03-24 2003-03-31 United Cancer Res Inst Vaccine indeholdende levende virus
JPH06234659A (ja) 1992-05-05 1994-08-23 Handai Biseibutsubiyou Kenkyukai 安定化生ワクチン
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
RU2126269C1 (ru) * 1992-06-04 1999-02-20 Мерк Энд Ко., Инк. Способ получения вакцины, способ получения свободной от клеток вакцины, способ культивирования клеток, питательная среда
WO1994021807A2 (en) 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
EP0872249A4 (de) 1995-03-17 2001-10-24 Hisamitsu Pharmaceutical Co Gentransferpräparation
JP2000507963A (ja) 1996-12-20 2000-06-27 メルク エンド カンパニー インコーポレーテッド 凍結乾燥ワクチン用安定剤

Also Published As

Publication number Publication date
GB9808922D0 (en) 1998-06-24
JP2002512970A (ja) 2002-05-08
ES2224646T3 (es) 2005-03-01
PT1071438E (pt) 2004-11-30
AU3718299A (en) 1999-11-16
DE69918283T2 (de) 2005-07-21
CA2329000C (en) 2010-03-23
EP1071438A2 (de) 2001-01-31
ATE269712T1 (de) 2004-07-15
WO1999055348A2 (en) 1999-11-04
CA2329000A1 (en) 1999-11-04
US6258362B1 (en) 2001-07-10
WO1999055348A3 (en) 1999-12-16
DK1071438T3 (da) 2004-10-25
EP1071438B1 (de) 2004-06-23

Similar Documents

Publication Publication Date Title
ATE269712T1 (de) Stabilisierte herpesvirusformulierung
IL124941A0 (en) Formulations of nerve growth factor suitable for lyophilization
MX9604907A (es) Vacuna de combinacion de virus para la enfermedad de newcastle.
NO20010576L (no) Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav
AU1198697A (en) Stabilizers for live vaccines
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
EP1140165A4 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
AU2497292A (en) Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
AU1271799A (en) Methods for preventing and treating bacterial infections using cellulose ace tatephthalate or hydroxypropyl methylcellulose phthalate excipients
IL201429A (en) Weakened live virus compositions and methods to reduce disabling live viruses
CY1108702T1 (el) Σκευασματα εμβολιων για τον ιο των ανθρωπινων θηλωματων
NO985094D0 (no) Polymerpulver som er redispergerbart i vandige l°sninger
AU4622693A (en) Potentiation of immunogenic response
CZ77995A3 (en) Derivatives of lipopeptides, process of their preparation and use
ES2035818T3 (es) Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso.
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
DE69928921D1 (de) Vormischungszusammensetzung zur bierklärung
EP0541692A4 (en) Herpes simplex virus vp16 vaccines
ES2056042T1 (es) Copolimeros solubles en agua de acetato de vinilo y acido maleamico. uso como fluidizadores o reductores de agua de alto alcance para suspensiones acuosas.
AR026637A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para uso en vacas gestantes
MXPA04001700A (es) Preparaciones flavanolignano de solubilidad incrementada.
EP1105157A4 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
TR200102168T2 (tr) BHV-1 geni silinmiş virüs aşısı.
DE69417717D1 (de) Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee